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Plenary Presentation 1 – Hepatitis C
PL-001 ISG15, an ubiquitin-like interferon stimulated
gene, promotes HCV production in vitro
Limin Chen*, Jing Sun, Larry Meng, Jenny Heathcote,
Aled Edwards, Ian McGilvray. University of Toronto, Toronto,
Canada
Objectives: Chronic hepatitis C virus (CHC) infection is treated
with interferon/ribavirin, but only a subset of patients re-
spond. The molecular mechanism of interferon resistance is not
well undertstood. We previously reported that treatment non-
responders have marked pre-treatment upregulation of a subset
of interferon stimulated genes (ISGs) in their livers, includ-
ing ISG15 (Chen, et al. Gastroenterology 2005) and discovered
ISG15/USP18 pathway is involved in interferon resistance (Ran-
dall, et al. Gastroenterology 2006). Here, we study the effect of
ISG15 on HCV production in J6/JFH1 culture system.
Methods: ISG15 expression and its conjugation (ISGylation) was
manipulated in two ways: up-regulated by plasmid transfec-
tion and inhibited by silencing the E1 activating enzyme Ube1L
using speciﬁc SiRNA. The effect of increased or decreased
ISG15/ISGylation on HCV RNA replication and viral particle pro-
duction was monitored by real-time PCR and NS5A staining,
respectively.
Results: Overexpression of ISG15 increased ISGylation in Huh7.5
cells and promoted HCV RNA replication and virion secretion. Si-
lencing Ube1L ablated ISGylation and inhibited HCV production.
This pro-HCV effect of ISG15 is not mediated through extracel-
lular free form ISG15 nor from perturbing the Jak/STAT signaling
pathway.
Conclusions: Contrary to many published studies on the anti-
viral activity of ISG15 in a number of viral models, ISG15 is a
pro-HCV molecule in vitro. This ﬁnding may help to explain why
increased ISG15 in the pretreatment liver tissue is correlated
with treatment failure, and suggests that manipulating ISG15
may be a potential approach for HCV therapy.
Plenary Presentation 2 – Bacterial Infections/
Antibiotics I
PL-002 Pharmacokinetic-pharmacodynamic proﬁling of
four antimicrobials against Gram-negative
bacteria collected from Shenyang, China
Yun Zhuo Chu1, Su Fei Tian*,1, Hua Nian1, Hong Shang1, Hong
Sheng Pan1, Bai Yi Chen2. 1Department of Laboratory Medicine,
2Division of Infectious Diseases, The First Afﬁliated Hospital of
China Medical University
Objectives: To examine common antimicrobial regimens used in
eradicationg certain nosocomial Gram-negative pathogens and
determine which ones are likely to be the most suitable as
empirical choices in Shenyang, China.
Methods: A 5000-subject Monte Carlo simulation was conducted
to determine the cumulative fraction of response (CFR) for
meropenem, imipenem, cefepime, piperacillin/tazobactam and
levoﬂoxacin against Escherichia coli, Klebsiella pneumoniae, En-
terobacter cloacae, Acinetobacter baumannii and Pseudomonas
aeruginosa collected in 2006 and 2007 from Shenyang.
Results: Meropenem and imipenem had the highest CFRs against
the Enterobacteriaceae (97–100%), followed by cefepime. No
antibiotic simulated regimen achieved optimal CFR against P.
aeruginosa and A. baumannii. Piperacillin/tazobactam dosed at
4.5g q8h achieved the lowest CFR against all bacteria.
Bactericidal CFR (%)
E. K. E. P. A.
coli pneumoniae cloacae aeruginosa baumannii
Meropenem 0.5g q6h 100 100 100 52 59
Meropenem 0.5g q8h 100 100 97 46 59
Meropenem 1g q8h 100 100 100 54 59
Imipenem 0.5g q6h 100 99 97 45 36
Imipenem 0.5g q8h 100 97 97 36 34
Imipenem 1g q8h 100 99 98 49 37
Cefepime 1g q8h 90 73 68 48 22
Cefepime 2g q8h 95 83 78 68 37
Cefepime 1g q12h 90 74 68 45 22
Piperacillin/tazobactam
4.5g q8h 71 33 34 11 8
Levoﬂoxacin 0.5g
every 24h 30 44 68 33 19
Conclusions: This study suggests that the carbapenems provide
the greatest likelihood of clinical success for the Enterobacteri-
aceae, and combination therapy might be needed when choosing
empirical therapy, especially when A. baumannii or P. aeruginosa
are suspected.
Plenary Presentation 3 – Parasitic/Gastro-intestinal
Infections
PL-003 Protective effect of a pvax1-Ts87 DNA vaccine
delivered in attenuated Salmonella typhimurium
against Trichinella spiralis infection in mice
Yaping Yang*,1, Xiaoqin Chen1, Zhifei Zhang1, Jing Yang1,
Jinsheng He2, Xinping Zhu1. 1Department of Parasitology,
School of Basic Medical Sciences, Capital Medical University,
Beijing, PR China; 2Institute of Bioscience and Biotechnology,
School of Science, Beijing Jiaotong University, Beijing, PR China
Objectives: Trichinellosis is a widespread zoonosis mainly caused
by Trichinella spiralis. Mucosal immunization is very important
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for preventing Trichinella spiralis infection. We have previously
reported that a recombinant Ts87 protein was considered as a
potential candidate vaccine for Trichinella spiralis. In this study
mucosal immune responses induced by SL7207/pvax1-Ts87 were
assessed.
Methods: We constructed a recombinant plasmid pvax1-Ts87,
and evaluated safety, stability of SL7207/pvax1-Ts87, a DNA
vaccine delivered in attenuated Salmonella typhimurium, and
immune responses induced by immunizing BALB/c mice orally
with SL7207/pvax1-Ts87 of 108 CFU dosage. After the ﬁnal boost,
mice were challenged orally with 500 Trichinella spiralis infec-
tive muscle larvae for per mouse.
Results: Oral immunization of mice with SL7207/pvax1-Ts87
elicited signiﬁcant elevation of intestinal secretory IgA and
serum anti-Ts87 IgG. The immunized mice exhibited a high ratio
of IgG1 to IgG2a. Splenocytes were isolated after the immu-
nization to determine the antigen-speciﬁc T-cell response by the
ELISPOT assay. The result showed that CD4+ T cells produced
IFN-γ, IL-4, IL-5, IL-6 and IL-10. Immunoﬂuorescent microscopy
revealed that the recombinant Ts87 protein was expressed in the
dendritic cells of mesenteric lymph nodes. Furthermore BALB/c
mice vaccinated with SL7207/pvax1-Ts87 demonstrated 29.8%
reduction in adult worm burden and muscle larval reduction
(34.2%) following Trichinella spiralis larvae challenge.
Conclusion: Our results demonstrated a SL7207/pvax1-Ts87 DNA
vaccine delivered in attenuated Salmonella typhimurium can
elicit speciﬁc immune response as well as provide effective
protection against Trichinella spiralis infection in mice.
Plenary Presentation 4 – Basic Science Including
Animal Models
PL-004 Protective effect of bone-marrow-derived
mesenchymal stem cells on ischemic reperfusion
injury of rat liver graft after reduced-size liver
transplantation
Hongli Song*, Xiaojing Song, Weiping Zheng, Zhongyang Shen.
Department of Organ Transplantation, Tianjin the First Central
Hospital
Objective: To observe the distribution and amount of bone-
marrow-derived mesenchymal stem cells (BMSCs) after reduced-
size liver transplantation in rats and study the effect of BMSCs in
promoting the recovery of ischemic reperfusion injury.
Methods: 1. BMSCs were isolated from femur in the rat by the
density gradient centrifugation and puriﬁed. 2. All reduced-size
liver transplantation models were divided into 2 groups (each
group having 18 recipients)as follow: Wistar donor liver to Wistar
recipient, 1ml (5×106/ml) BMSCs of the third generation and
labeled (treat group) and 1ml PBS (control group) were injected
into portal vein, respectively. At the 2nd, 3rd and 7th day after
transplantation, liver and serum samples were collected. By us-
ing biochemistry, Immunohistochemistry, Flow CytoMeter and the
biochemical indicator were detect and counted. The distribution
of BMSCs in the frozen section was observed by ﬂuorescence.
The mechanism of the reparation of ischemic reperfusion injury
was explored through observation of the trace of CFSE-labeling
donator’s BMSCs in recipient’s body.
Results: The injured hepatic tissues were repaired. The green
ﬂuorescent cells were found in the recovery of the host liver tis-
sue, central veins and sinus hepaticus. The number of tetraploid
cell in treat group was signiﬁcantly inhibited in control group
(p=0.024).
Conclusion: BMSCs can successfully reside in the liver of rats and
the homing status of BMSCs is closely associated with quantity
of stem cells and the damage status of liver. BMSCs can protect
hepatic ischemic reperfusion injury.
Plenary Presentation 5 – Hepatitis B I
PL-005 Proﬁle of HBsAg levels in patients with dual
hepatitis B virus and hepatitis C virus infection
treated with peginterferon alfa-2a and ribavirin
Chun-Jen Liu*,1, Wan-Long Chuang2, Chuan-Mo Lee3,
Ming-Lung Yu2, Sheng-Nan Lu3, Shun-Sheng Wu4, Li-Ying Liao5,
Hsing-Tao Kuo6, You-Chen Chao7, Shui-Yi Tung8, Sien-Sing Yang9,
Jia-Horng Kao1, Chen-Hua Liu1, Pei-Jer Chen1,
Ding-Shinn Chen1. 1National Taiwan University College of
Medicine and National Taiwan University Hospital; 2Kaohsiung
Medical University Hospital; 3Chang Gung Memorial
Hospital-Kaohsiung; 4Changhua Christian Hospital; 5Taipei City
Hospital; 6Chi Mei Medical Center; 7Tri-Service General
Hospital; 8Chia-Yi Chang Gung Memorial Hospital; 9Cathay
General Hospital
Objectives: Our recent study showed the potential for peginter-
feron alfa-2a and ribavirin combination therapy in these patients
– a high rate of HBsAg clearance was observed (11%) 24 weeks
post treatment in patients with HBeAg-negative disease. We
assessed HBsAg levels at baseline, during and after the end of
treatment.
Methods: HBsAg-positive patients coinfected with HCV received
peginterferon alfa-2a (180μg/week) for 48 weeks (in HCV geno-
type 1 in combination with ribavirin 1000/1200 mg/day) or for
24 weeks (for HCV genotype 2/3 in combination with ribavirin
800 mg/day). HBsAg was quantiﬁed at baseline, weeks 4, 12, end
of treatment (24 or 48 weeks) and 24 weeks post treatment (48
or 72 weeks) using the Abbott Architect assay. HBsAg data were
available for 120 of the 161 dual-infected patients.
Results: Of 120 patients, 74 received treatment for 48 weeks
and 46 received treatment for 24 weeks. Pretreatment median
serum HBsAg was 156 IU/mL. At the end of follow up, 14 patients
(11.7%) had cleared HBsAg. Baseline HBsAg levels in approxi-
mately 80% of patients clearing HBsAg at end of therapy or follow
up were low (<1 IU/mL). 21 (46%) patients who had received
therapy for 24 weeks achieved HBsAg levels <10 IU/mL at the
end of follow-up; 37 (50%) patients who had received therapy
for 48 weeks achieved HBsAg levels <10 IU/mL at the end of
follow-up.
Conclusions: HBV/HCV coinfected patients treated for 24 or 48
weeks with low baseline levels of HBsAg could potentially clear
HBsAg.
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PL-006 Study on detection of resistant genes in common
clinical bacteria used a multiplex real-time PCR
and melt temperature curve assay
Xuedong Lu*, Chengjing Xia, Lie Huang, Qiong Wang, Jian Liu,
Guangcheng Lin, Jiehong Wei. Shenzhen Futian Hospital
Objective To construct a multiple detection platform for
macrolides and beta-lactamases resistant genes of clinical bac-
teria.
Methods To detected ermA, ermB, ermC, msrA genes for
macrolides and tem, shv, ctx-m-1 team, ctx-m-9 team genes
for beta-lactamases resistant genes screening by using multi-
plex real-time SYBR Green I PCR combining melt temperature
curve assay. Resistant genes were detected and the results were
compared with phenotype results and sequencing results.
Results All the resistance genes of positive bacteria were demon-
strated by the optimize multiplex detection platform. The sen-
sibility was 104 CFU for multiple resistant gene bateria and 103
CFU for single resistant gene bateria. The detection results of
